Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets hold on to their gains
Wed, 22 Dec 11:30 am

After starting today’s session on a positive note, Indian indices have managed to hold on to their gains. However, other key Asian markets are trading mixed. Currently, heavyweights in the Sensex are trading flat with stocks from the realty and metals space leading the gains. However, stocks from the IT and consumer goods space are trading flat.

Currently, the BSE-Sensex is trading up by around 52 points, while the NSE-Nifty is up by about 10 points. There has been some buying interest amongst the mid and small cap stocks as well with the BSE-Midcap and BSE-Smallcap indices trading higher by 0.6% and 0.8% respectively.

Pharma stocks are trading mixed with Ranbaxy and Wockhardt leading the gains. However, Dr Reddy’s and Indoco Remedies are trading weak. Dr Reddy’s has entered into a licensing, technology transfer and marketing agreement with R-Pharm of Russia. Apart from manufacturing finished & bulk drugs, R-Pharm also undertakes R&D of innovative pharmaceutical productsand technologies. The collaboration between the two firms is in the area of high technology and will work on a profit sharing model. The agreement will allow joint development of products and knowledge sharing between the two companies. Collaboration with R-Pharm will not only strengthen Dr Reddy’s presence in Russia but will also allow it to import and market R-Pharm products in India thereby enlarging its overall product portfolio.

Oil & Gas stocks are trading firm led by BPCL and Essar Oil. However, Petronet LNG and Gujarat State Petronet are trading weak. RIL and Russia’s leading petrochemical company SIBUR have announced a JV for production of butyl rubber in India. The production will be undertaken at RIL’s integrated petrochemical site in Jamnagar with an initial capacity of 100,000 tones. Initial investment in the project is estimated to be US$ 450 m and the plant is expected to be commissioned by 2013 with RIL having a majority stake in the JV. SIBUR is expected to bring its proprietary technology on to the table for rubber polymerization while RIL will supply monomers and provide infrastructure facilities for manufacturing of butyl rubber. RIL’s venture to set up a rubber plant in India is expected to meet the long standing demand of the Indian tyre and rubber industry.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets hold on to their gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.